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Developmental anomalies of the ocular anterior chamber angle may lead to an incomplete development of the structures that
form the conventional aqueous outﬂow pathway. Thus, disorders that present with such dysfunction tend to be associated with
glaucoma. Among them, Axenfeld-Rieger (ARS) malformation is a rare clinical entity with an estimated prevalence of one in
every 200,000 individuals. The changes in eye morphogenesis in ARS are highly penetrant and are associated with 50% risk of
developmentofglaucoma.MutationsinthecytochromeP4501B1(CYP1B1)genehavebeenreportedtobeassociatedwithprimary
congenital glaucoma and other forms of glaucoma and mutations in pituitary homeobox 2 (PITX2) gene have been identiﬁed
in ARS in various studies. This case was negative for PITX2 mutations and compound heterozygote for CYP1B1 mutations.
Clinical manifestations of this patient include bilateral elevated intraocular pressure (>40mmHg) with increased corneal diameter
(>14mm) and corneal opacity. Patient also had iridocorneal adhesions, anteriorly displaced Schwalbe line, anterior insertion
of iris, broad nasal bridge and protruding umbilicus. This is the ﬁrst study from north India reporting CYP1B1 mutations in
Axenfeld-Rieger syndrome with bilateral buphthalmos and early onset glaucoma. Result of this study supports the role of CYP1B1
as a causative gene in ASD disorders and its role in oculogenesis.
1.Introduction
Developmental anomalies of the anterior chamber angle
may lead to an incomplete development of the struc-
tures that form the conventional aqueous outﬂow pathway.
Thus, disorders that present with such dysfunction tend
to be associated with glaucoma. Among them, Axenfeld-
Rieger (ARS) malformation is a rare clinical entity with
an estimated prevalence of one case in every 200,000
individuals [1]. The term ARS describes a group of con-
genital diseases that were historically summarized under
the broader heading of anterior chamber cleavage syn-
dromes (including Axenfeld anomaly, Rieger anomaly, and
Rieger syndrome). ARS represents a spectrum of disorders
involving ocular and, in some cases, extraocular structures
caused by disruption of migration and diﬀerentiation of
neural crest cells [2]. Several anterior segment anomalies
known to involve tissues derived from neural crest cells
have been described in literature and are thought to be
due to inadequate regression of tissues and/or failure in
diﬀerentiation, which results in distortions of normal irido-
corneal angle anatomy. These disorders include Axenfeld-
Rieger syndrome, Peters anomaly, familial iris hypoplasia
associated with glaucoma, and iridogoniodysgenesis. The
ocular structures involved in ARS include the cornea
(posterior embryotoxon), the iridocorneal angle (peripheral
iridocorneal adherences and ultrastructural abnormalities of
the trabecular meshwork), and the iris (peripheral adhesions




and oligodontia) and facial malformations (hypoplasia of
the maxillary bones) [3]. Redundant periumbilical skin,2 Case Reports in Medicine
hypospadias, as well as other less frequent systemic alter-
ations, may also be observed in ARS [4–6]. Pituitary
homeobox 2 (PITX2) gene mutations have been identiﬁed
in ARS in many studies [7, 8]. The changes in eye mor-
phogenesis in ARS are highly penetrant and, anecdotally,
have been associated with an approximately 50% risk of the
development of glaucoma [9]. Glaucoma may appear during
childhood, but it is more common during adolescence or at
the beginning of adulthood. Glaucoma secondary to ARS
is diﬃcult to manage and may result in severe damage to
the optic disc and visual ﬁeld [3]. In 1997, Stoilov et al.,
described structural alterations in the CYP1B1 gene (MIM
601771), a member of the cytochrome P450 enzyme family,
in patients with congenital glaucoma linked to the GLC3A
locus[10].MutationsintheCYP1B1genehavebeenreported
to be associated with other forms of glaucomas, including
Peters’ anomaly [11–13], and to act as a modiﬁer gene in
juvenile open-angle glaucoma [14]. Considering that Peters’
anomaly is characterized by anterior ocular malformation
because of defective migration of neural crest cells, it is
possible to hypothesize that CYP1B1 gene could play a role
in the pathogenesis of ARS.
2.CaseDetails
T h ep r o b a n dw a sa9m o n t h so l dm a l eo ﬀspring who pre-
sented with the bilateral buphthalmos with corneal edema.
He had intraocular pressure of 48mmHg and 40mmHg in
the right and left eye, respectively, with corneal diameter of
14.0 × 14.5mm and 15.0 × 15.0mm. He had iridocorneal
adhesions (Figures 1 and 2), anteriorly displaced Schwalbe
line (Figures 1 and 2), and anterior insertion of iris.
On general examination, he had broad nasal bridge and
protruding umbilicus. On the basis of ocular and general
examination clinical diagnosis of congenital glaucoma with
Axenfeld-Rieger syndrome was made. The proband under-
went bilateral trabeculotomy + trabeculectomy + mitomycin
C (MMC) treatment. Patient is under regular follow up since
then. After two years of follow-up he had IOP of 34mmHg
and 20mmHg in the right and left eye, respectively, with
0.7:1 optic nerve cupping in both eyes. Recent corneal
diameter was 15.0 × 14.0mm in both eyes. He also had
malaligned teeth.
3. Methods
The entire coding region including exon-intron boundaries
of CYP1B1 and PITX2 gene from patient and his parents
were ampliﬁed. PCR for CYP1B1 gene was done by using
three sets of overlapping primers described elsewhere [15].
The primers used were set I (1F-1R, 786bp), set II (2F-
2R, 787bp), and set III (3F-3R, 885bp). PCR ampliﬁcations
for primer sets I and II were performed in a 40µLv o l u m e
containing 1.0µLo f2 0µMs t o c ks o l u t i o nf o re a c hp r i m e r ,
100ng of genomic DNA, 1 unit of Taq polymerase (Banglore
Genei), 0.1mM of each dNTP, 4µL of 10X PCR buﬀer (with
15mM MgCl2), and 4µL of dimethyl sulphoxide (Sigma),
by means of 35 cycles of ampliﬁcation, each consisting of
Figure 1: Slit-lamp photograph of eye showing anterior segment
dysgenesis.
Figure 2: Gonioscopic photograph of eye showing anteriorly
displaced Schwalbe line (white arrow) and irido-corneal adhesions
(black arrow).
30 seconds denaturation at 94◦C, 30 seconds annealing at
56◦C, and 1 minute extension at 72◦C[ 14], while conditions
for set III were initial denaturation at 94◦Cf o r3m i n u t e s
followed by 30 cycles each at 94◦C for 30 seconds, 60◦Cf o r
30 seconds, and 72◦C for 1 minute and ﬁnal extension at
72◦C for 5 minutes. PCR primers for PITX2 gene (Table 1)
were designed using NCBI PRIMER3 program (available
at http://www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR
ampliﬁcations for PITX2 all primer sets were performed in
a4 0 µL volume containing 1.0µLo f2 0 µMs t o c ks o l u t i o n
for each primer, 100ng of genomic DNA, 1 unit of Taq
polymerase (Banglore Genei), 0.1mM of each dNTP, and
4µL of 10X PCR buﬀer (with 15mM MgCl2), by means
of 40 cycles of ampliﬁcation, each consisting of 30 seconds
denaturation at 94◦C, 50 seconds annealing at 56–57◦C, and
50 seconds extension at 72◦C and ﬁnal extension at 72◦Cf o r
5m i n u t e s .
Ampliﬁed PCR products were puriﬁed using a gel/PCR
DNA fragments extraction kit (number DF100; Geneaid
Biotech Ltd., Sijhih City, Taiwan). Puriﬁed PCR productsCase Reports in Medicine 3
Table 1: PITX2 primers used in this study.
Primer Name Primer Sequence Product Size
PITX1F 5  CAC TCC CGC TGC CAT TGC GT 3 
618bp
PITX1R 5  GGG GGC TTC GGT ACA CAG CG 3 
PITX2F5   ACC GGG GAG GCG CAG AAA GA 3 
635bp
PITX2R5   GCC GAG GTT TGC TGG AGC GT 3 
PITX3F 5  GCA GCC CAG CTC TTC CAC GG 3 
559bp
PITX3R 5  GTG AGA TCG CGG GAT GGC GG 3 
PITX4F 5  CTG CGC TTG GTG GAG ACC CG 3 
812bp
PITX4R 5  GTT GCC CCA TCC GGC AAG GT 3 
130 140
A C T C G A G T G C A G
(a)
120
A C TTG A G T G C A G
(b)
Figure 3: DNA sequence chromatogram of CYP1B1 exon 3
equivalent to codon 354–357. (a) The reference sequence derived
from control is shown. (b) Sequence derived from ARS patient
shows heterozygous c.1063C > T, which predicts a codon change
CGA > TGA and heterozygous p.R355X, a non-sense mutation.
were sent for sequencing to MCLAB (Molecular Cloning
Laboratories, South San Francisco, CA). CYP1B1 DNA
sequences were analyzed against the CYP1B1 gene refer-
ence sequence ENSG00000138061 (available at http://
www.ensembl.org/Homo sapiens/Gene/Sequence?g=ENSG0
0000138061) and PITX2 DNA sequences against PITX2
gene reference sequence ENSG00000164093 (available at
http://www.ensembl.org/Homo sapiens/Gene/Sequence?g=
ENSG00000164093) using ClustalW2 (multiple sequence
alignment program for DNA; European Molecular Biology
Laboratory (EMBL)-European Bioinformatics Institute
(EBI).
4. Computational Assessment of
Missense Mutations
Two homology based programs PolyPhen (Polymorphism
Phenotyping), available at http://genetics.bwh.harvard.edu/
pph/, and SIFT (Sorting Intolerant From Tolerant) analysis
tool, available at http://sift.jcvi.org/ were used to predict
the functional impact of missense changes identiﬁed in
this study. PolyPhen structurally analyzes an amino acid
polymorphism and predicts whether that amino acid change
is likely to be deleterious to protein function [16–18]. The
prediction is based on the position-speciﬁc independent
counts (PSIC) score derived from multiple sequence align-
ments of observations. PolyPhen scores of >2.0 indicate the
polymorphism is probably damaging to protein function.
Scores of 1.5–2.0 are possibly damaging, and scores of <1.5
are likely benign. SIFT is a sequence homology-based tool
that sorts intolerant from tolerant amino acid substitutions
and predicts whether an amino acid substitution in a
protein will have a phenotypic eﬀect [19–22]. SIFT is
based on the premise that protein evolution is correlated
with protein function. Positions important for function
should be conserved in an alignment of the protein family,
whereas unimportant positions should appear diverse in an
alignment. Positions with normalized probabilities less than
0.05 are predicted to be deleterious and those greater than or
e q u a lt o0 . 0 5a r ep r e d i c t e dt ob et o l e r a t e d .
5. Results
PITX2 gene analysis showed heterozygous T > A change
at g.11553261 (in Intron 5). No pathogenic PITX2 muta-
tion was identiﬁed in this patient. CYP1B1 analysis
showed presence of two heterozygous pathogenic mutations
(p.Arg355Stop + p.Arg368His). Both of these mutations
(CYP1B1) have been reported in cases with primary congen-
ital glaucoma [15]. Father of the proband was negative for
these mutations but mother was heterozygous for p.R368H
mutation.
5.1. Arginine355Stop (p.R355X) Mutation. In this muta-
tion, a single-base cytosine (C) was replaced by thymine
(T) (Figure 3) at genomic position g.38151938; coding
nucleotide number c.1063. This resulted in a codon change
from CGA to TGA and p.R355X a non-sense mutation
in CYP1B1 protein. This resulted in a truncated CYP1B1
protein of 354 amino acids.
5.2. Arginine368Histidine (p.R368H) Mutation. A single-
base guanine (G) was replaced by adenine (A) at genomic
position g.38151898; coding nucleotide number c.1103.
This resulted in a codon change from CGT to CAT and4 Case Reports in Medicine
170 180
G A CC G T C T G CCT
(a)
160
G A CC A T C T G CCT
(b)
Figure 4: DNA sequence chromatogram of CYP1B1 exon 3
equivalent to codon 367–370. (a) The reference sequence derived
from control is shown. (b) Sequence derived from ARS patient
shows heterozygous c.1103G > A, which predicts a codon change
from CGT > CAT and heterozygous p.R368H mutation.
amino acid change from arginine to histidine (p.R368H)
a nonsynonymous mutation (Figure 4). PSIC score of this
mutation was 2.653 indicating that this change is probably
damaging to protein function. SIFT score of p.R368H is 0.00
and is predicted to be deleterious for the protein function.
Since, missense mutation in PITX2 was absent no
computational assessment was done for PITX2 protein.
6. Discussion
Over the last several years, the identiﬁcation of genes and
loci involved in the diﬀerent forms of glaucoma has led
to a better understanding of the pathogenetic mechanisms
of primary open-angle glaucoma, congenital glaucoma,
and developmental glaucoma, such as the one associated
with ARS [2]. Although AR has an autosomal dominant
inheritance there have been reports of sporadic cases in the
literature [23].
Mutations of CYP1B1 are a major cause of primary
congenital glaucoma in various studies from diﬀerent popu-
lations [15, 24–29]. CYP1B1 is a member of the cytochrome
P450 super family of drug metabolizing enzymes. It catalyzes
several oxidative reactions, some of which are biosyn-
thetic, producing necessary hormones or compounds of
intermediary metabolism in most living organisms [30].
It also metabolizes vitamin A in two steps to all-trans-
retinal and all-trans-retinoic acid. The latter is a potent
morphogen and regulates in utero development of tissue
growth and diﬀerentiation [31–33]. It is involved in the
metabolism of the endogenous and exogenous substrates
that take part in early ocular diﬀerentiation [31–33]. This
case was compound heterozygote for p.R355X and p.R368H
mutations. In p.R355X mutation, a truncated protein of 354
aminoacidsisproduced.Thearginineresidueatposition355
lies in the carboxyl terminal of the J helix, carboxyl terminal
of the J helix is involved in the functionally important heme-
binding domain. This change (p.R355X) was ﬁrst reported
in PCG in Germany and after that from India [15, 34].
This truncating mutation results in a loss of the heme-
binding domain and a functionally inactive protein [10, 34–
36]. Mutations in CYP1B1 gene emerged as a largest cause of
PCG and p.R368H has been reported as most predominant
CYP1B1 mutation in PCG in Indian population [24].
Arginine residue at 368 position lies in between the
helices J and K in an exposed loop [24, 29]. Consequences
of this change are not immediately apparent except that
the positively charged amino acid arginine is replaced by
histidine whose charge state depends upon its protonation
state. In the WT, arginine at 368 interacts with G-365, D-
367, V-363, and D-374. Because of the p.R368H mutation,
interactions between D-367 and D-374 are weakened [36].
PolyPhen and SIFT score of p.R368H showed that this muta-
tion is deleterious for the protein function. An alteration of
CYP1B1 expression due to a sequence change might alter the
metabolicactivityofCYP1B1,thuscauseoculardevelopment
defects. Membrane-bound cytochromes, such as CYP1B1,
have a molecular structure containing a transmembrane
domain located at the N-terminal end of the molecule.
This is followed by a proline-rich “hinge” region, which
permits ﬂexibility between the membrane-spanning domain
and the cytoplasmic portion of the protein molecule. The
COOH-terminal ends are highly conserved among diﬀerent
members of the cytochrome P450 super-family [37]. This
family contains a set of conserved core structures responsible
for the heme-binding region of these molecules. The heme-
binding region is essential for the normal function of
every P450 molecule. Between the hinge region and the
conserved core structure lies a less conserved substrate-
binding region. The cytochrome P450 protein functions like
any classical enzyme molecule [32, 33]. Mutations aﬀect-
ing such enzymes generally produce recessive phenotypes
because in heterozygous subjects the normal allele is capable
of compensating for the mutant allele. Mutations in the
CYP1B1 protein interfere with the integrity of the CYP1B1
protein as well as its ability to adopt a normal conformation
and to bind heme; for example, induced mutations in the
hinge region have previously been reported to interfere
with the heme-binding properties of the cytochrome P450
molecules [38].
First report of mutations in CYP1B1 as a cause for Rieger
Anomaly was published in 2006 by Chavarria-Soley et al.
[39]. Three reports exist of CYP1B1 mutations in Peters
Anomaly; patients are either compound heterozygotes [11,
13] or homozygous in consanguineous families [12].
Segregation of both ARS and Peters’ anomaly in the same
family has been reported previously [40–43]. Therefore, ARS
and Peters’ anomaly are discussed to be allelic variants and
part of the single disease spectrum of anterior segment
dysgenesis (ASD) rather than representing distinct entities.
This hypothesis is supported by clinical and genetic ﬁndings
as well as by the embryonic pathogenesis of ASD. First,
several clinical features like corectopia or angle anomalies
are common both in ARS and in Peters’ anomaly. Second,Case Reports in Medicine 5
mutations in FKLH7/FOXC1 genes (as well as mutations in
other genes implicated in ASD) are associated with clinically
variablemanifestationslikeARS[44,45],primarycongenital
glaucoma [24–26], and Peters’ anomaly [40]. Third, ASD is
genetically heterogeneous.
Peters’ anomaly, for instance, has been associated with
mutations in PAX6 [42, 46–48], CYP1B1 [11–13, 49], and
FOXC1[43].Fourth,thereisgrowingevidencethattheASDs
are neural crestopathies that result from a developmental
arrestofspeciﬁcanteriorsegmenttissuesderivedfromneural
crest cells [3]. Mutations in CYP1B1 could be contributory
in up to 20% of cases of Peters anomaly. Since this case was
negative for pathogenic PITX2 mutations, therefore, results
of this study support the role of CYP1B1 as a causative
geneinASDassuggestedbypreviousstudies[11–13, 39, 49].
Furthermore, this emphasizes the broad range of phenotypic
expression for CYP1B1 mutations, and its role in eye
development.
7. Conclusion
This is the ﬁrst study from India reporting CYP1B1 muta-
tions in Axenfeld-Rieger syndrome with bilateral buphthal-
mos and early onset glaucoma. Result of this study supports
the role of CYP1B1 as a causative gene in ASD disorders
[11–13, 39, 49] and it emphasizes the broad range of
phenotypic expression for CYP1B1 mutations, and its role in
oculogenesis.
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